{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 118 of 169', '35. Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, Adkinson FN Jr, Bock SA, Branum A, et', 'al. Second symposium on the definition and management of anaphylaxis: Summary report', '-- Second National Institute of Allergy and Infectious Diseases/Food Allergy and', 'Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-397.', '36. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification', 'Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the', \"FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;\", '164(7):1035-1043.', '37. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial', 'community variation in human body habitats across space and time. Science. 2009;', '326(5960):1694-1697.', '38. Cardona ID, Cho SH, Leung DY. Role of bacterial superantigens in atopic dermatitis:', 'implications for future therapeutic strategies. Am J Clin Dermatol. 2006;7(5):273-279.', '39. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in', 'the skin microbiome associated with disease flares and treatment in children with atopic', 'dermatitis. Genome Res. 2012;22(5):850-859.', '40. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work', 'productivity and activity impairment instrument. Pharmacoeconomics.', '1993;4(5):353-365.', '41. World Health Organization. WHO model prescribing information: drugs used in skin', 'diseases. Geneva. 1997.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 119 of 169', 'Appendix 1: Protocol summary', 'Name of', 'Tralokinumab', 'investigational', 'medicinal product', 'Name of active', 'Human recombinant IL-13 monoclonal antibody.', 'substance', 'Title of trial/', 'A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the', 'trial ID/', 'efficacy and safety of tralokinumab monotherapy in subjects with', 'EudraCT no./', 'moderate-to-severe atopic dermatitis (AD) who are candidates for systemic', 'ClinicalTrials.gov', 'therapy - ECZTRA 1 (ECZema TRAlokinumab trial no. 1) /', 'no.', 'LP0162-1325 / 2016-004200-65 / NCT03131648', 'International', 'Andreas Wollenberg, Prof. Dr. med. Dr. h.c.', 'coordinating', 'investigator', \"Sponsor's name/\", 'LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark', 'address', 'Estimated number', 'Approximately 130 sites in Europe, North America, and Japan.', 'of trial sites and', 'distribution', 'Main objectives', 'Primary objective:', 'To evaluate the efficacy of tralokinumab compared with placebo in treating', 'moderate-to-severe AD.', 'Secondary objectives:', 'To evaluate the efficacy of tralokinumab on severity and extent of AD, itch,', 'and health related quality of life compared with placebo.', 'Maintenance objective:', 'To evaluate maintenance of effect with continued tralokinumab dosing up to', '52 weeks compared to placebo for subjects achieving clinical response at', 'Week 16.', 'Methodology', 'Overview', 'The trial will consist of a screening period of 2 to 6 weeks (Weeks -6/-2 to 0),', 'an initial treatment period of 16 weeks (Weeks 0 to 16) and a maintenance', 'treatment period of 36 weeks (Weeks 16 to 52). A 14-week off-treatment', 'follow-up period for the assessment of safety is also included (Weeks 52 to 66).', 'All subjects will use an emollient at least twice daily for at least 14 days before', 'randomisation and will continue this treatment throughout the trial.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}